Geneos Wealth Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Geneos Wealth Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,365	Closed	-$12.2K	–	2556
2025 Q2	$12.2K	Sell	1,365 -2,011	-60%	-$18.7K	﹤0.01%	2242
2025 Q1	$25.3K	Buy	3,376 +2,554	+311%	+$20.6K	﹤0.01%	2230
2024 Q4	$6.18K	Sell	822 -500	-38%	-$3.8K	﹤0.01%	2249
2024 Q3	$10K	Buy	1,322 +822	+164%	+$6.25K	﹤0.01%	1844
2024 Q2	$3.09K	Hold	500	–	–	﹤0.01%	1805
2024 Q1	$2.54K	Hold	500	–	–	﹤0.01%	1859
2023 Q4	$3K	Buy	+500	New	+$2.9K	﹤0.01%	1848
2020 Q3	–	Sell	-1,200	Closed	-$5K	–	2632
2020 Q2	$5K	Buy	+1,200	New	+$4.79K	﹤0.01%	2127

Other funds holding BCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Geneos Wealth Management's BCRX Position: Q3 2025 in Review

Geneos Wealth Management sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2025, closing a stake of 1,365 shares — an estimated $12.2K sold.

Geneos Wealth Management first reported a position in BCRX in Q2 2020 and held it in 8 quarters. The position peaked at $25.3K in Q1 2025. 286 funds tracked by Wall St. Rank hold BCRX as of Q3 2025.

Geneos Wealth Management reported no remaining BioCryst Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Geneos Wealth Management sold 1,365 BioCryst Pharmaceuticals shares in Q3 2025, an estimated $12.2K.
Geneos Wealth Management first reported a position in BioCryst Pharmaceuticals in Q2 2020 and held it in 8 quarters.
Geneos Wealth Management's BioCryst Pharmaceuticals position peaked at $25.3K in Q1 2025.
286 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2025.

Based on Geneos Wealth Management's 13F filing for Q3 2025, filed 22 Oct 2025.